All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
11 results for "Cancer" and "Endocrine Cancers" and "Kidney"
A Phase I, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 Administered Twice Daily for 14 Days to Patients with Advanced Solid Tumors
Phase I, First-in-human Study of Oral TP-1287 in Patients With Advanced Solid Tumors
Protocol No
TOLERO-TP-1287-101
Bicycle-BT5528-100 Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT5528 in Patients with Advanced Malignancies Associated with EphA2 Expression
This study is a Phase I/II, first-in-human, open-label dose-escalation study of BT5528 given as a single agent (Parts A-1 and B-1) and in combination with nivolumab (Parts A-2 and B-2). There are two parts to this study: Part A, dose escalation and Part B, dose expansion.
Protocol No
BICYCLE-BT5528-100
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX-106 and INBRX-106 in Combination with Pembrolizumab in Subjects with Locally Advanced or Metastatic Solid Tumors
To assess the safety, tolerability, dose-limiting toxicities (DLTs), and determine the maximum tolerated dose of INBRX-106 as a single agent administered as an intravenous infusion and in combination with pembrolizumab.
Protocol No
INHIBRX-PH1-INBRX-106
Phase 1 First-in-Human (FIH) Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX-8064, as Monotherapy and in Combination with a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects with Advanced Refractory Solid Tumor Malignancies
Phase 1 First-in-Human (FIH) Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX-8064, as Monotherapy and in Combination with a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects with Advanced Refractory Solid Tumor Malignancies.
Protocol No
JOUNCE-JTX-8064-101
A Phase 1 Trial of Hydroxychloroquine (HCQ) in Combination with Abemaciclib and Endocrine therapy in HR+/Her 2- Advanced Breast Cancer after a Lead in Dose Escalation Cohort of HCQ and Abemaciclib in Advanced Solid Tumors
A Phase 1 Trial of Hydroxychloroquine (HCQ) in Combination with Abemaciclib and Endocrine Therapy in HR+/Her 2- Advanced Breast Cancer after a Lead in Dose Escalation Cohort of HCQ and Abemaciclib in Advanced Solid Tumors
Protocol No
IIT-MENON-COINCIDE
Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial PLATFORM TRIAL
This study will evaluate the efficacy and safety of multiple therapies that are selected
using somatic alterations and potential predictive biomarkers identified via NGS assays
in patients with solid tumors.
using somatic alterations and potential predictive biomarkers identified via NGS assays
in patients with solid tumors.
Protocol No
HOFFMANN-BO41932-TAPISTRY
Phase 1 Multicenter, Open-Label, Dose Escalation Study and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of STP705 Administered Intratumorally in Cholangiocarcinoma, Hepatocellular Carcinoma or Liver Metastases in Subjects With Advanced / Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy
This clinical trial tests an investigational drug, STP705, that has shown through laboratory experiments to silence TGF-1 and COX-2 gene expressions, enzyme proteins believed to speed cancer growth in some cancers, which may result in tumor shrinkage when administered.
Protocol No
SIRNAOMICS-SRN-705-005
Phase 1/1b Study to Evaluate the Safety and Activity of TTX-030 (Anti-CD39) in Combination with Pembrolizumab or Budigalimab and/or Chemotherapy in Subjects with Advanced Solid Tumors
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
Protocol No
TRISHULA-TTX-030-002
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
Collection of research data and samples from patients who experience immunotherapy side effects
Protocol No
ALLIANCE-A151804
An Open-Label, Multiple-Dose, Dose- Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects with Solid Tumors or Lymphoma
This is a Phase 1 study of orally administered VMD-928 in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curative therapy exists
Protocol No
VMONCOLOGY-VMO-01C
A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Protocol No
TORAY-950P1V02